Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — FY2025 Earnings Presentation
29 slides from Vitrafy Life Sciences's earnings presentation, Aug 5, 2025
Slide 1: Financial Results Presentation FY25
Financial Results Presentation FY25 5 August 2025 Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com Strictly Private & Confidential 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Eligible recipients Statements in this presentation are made only as at the date of this presentation and the information This presentation is provided to you as an investo
Slide 3: Important Notice and Disclaimer (cont.)
Important Notice and Disclaimer (cont.) Not financial product advice Forward-looking statements speak only as at the date of this presentation and to the full extent Reliance should not be placed on the information or opinions contained in this presentation. permitted by law, the Company and its res
Slide 4: Today's Presenters
Today’s Presenters Brent Owens Kate Munnings Simon Martin Sonia Petering Chief Executive Officer (from 1 Chief Executive Officer Chief Financial Officer Chair September 2025), Co-Founder (until 1 September 2025) 25 years’ experience in executive Extensive experience as a non- Creative entrepreneur a
Slide 5: Vitrafy addresses the vital global need for enhanced cryopreservation solutions
Vitrafy addresses the vital global need for enhanced cryopreservation solutions. Vitrafy’s mission is to improve the quality of healthcare treatments by providing effective cryopreservation technology, preserving life. 5
Slide 6: Results and Operational Overview
1 Results and Operational Overview 6
Slide 7: FY25 Delivered on IPO Commitments
FY25 Delivered on IPO Commitments Operational Highlights Financial Position Market development Progress in FY25 Technology development Progress in FY25 $29.6m Total cash and liquid assets • Expansion of commercial activity in animal • VCU2 detailed design well advanced, reproduction, with significan
Slide 8: Market Development
Market Development Quality and Consistency Animal Reproduction Blood & Blood Products Cell & Gene Therapies 8
Slide 9: Commercialisation and Priority Applications
Commercialisation and Priority Applications Vitrafy’s next-generation cryopreservation technology has widespread applications Bovine & across a variety of Market aquaculture Blood platelets Cell & gene therapy biological materials. Regulatory status Global Market Unlocked Unregulated unlocked Unregu
Slide 10: Operational Highlights – Blood Platelets
Operational Highlights – Blood Platelets Completed third party Post Thaw Recoveries studies on commercial Completed Phase 1 Study scale volumes; progressing 100% with outstanding results towards commercialisation 90% with partner, U.S Military ‘Game-changing’ opportunity 80% in platelet 70% 60% Stud
Slide 11: Operational Highlights – Blood Platelets
Operational Highlights – Blood Platelets “ Further endorsement of Vitrafy technology from U.S. Military via co-presentation of study Despite the limited sample abstract at multiple blood conferences in the size of our initial phase 1 short term. study, our results suggest that cryopreserved platelet
Slide 12: Operational Highlights – Cell and Gene Therapies
Operational Highlights – Cell and Gene Therapies Vitrafy technology proven PBMC* Validation Data (raw material) to exceed current industry Internal testing proves standards – established a PBMC Vitrafy Protocol Results Vitrafy’s value proposition in priority market segments far data set critical for
Slide 13: Operational Highlights – Aquaculture
Operational Highlights – Aquaculture Growth in commercialisation Aquaculture Comparison Dtudy Q3 & Q4 FY25 with existing and new Revenue growth in partners; validated 100 commercial activities competitive advantage. 90 80 Consistent fertilisation 70 outcomes across multiple FY25 cycles Fertilisation
Slide 14: Operational Highlights – Bovine
Operational Highlights – Bovine Value proposition proven; Post Thaw Recovered Semen Motility exploring global market Continuing to build opportunities 70% application data sets that support the presentation to market 60% Continuing collaboration – onsite trials ongoing with Select Sires, Inc. 50% Ex
Slide 15: Commercialisation Approach
Commercialisation Approach Vitrafy has developed a staged pipeline to progress Business Development its innovative technology with partners to a point Term Sheet & Detailed Program of commercialisation. Negotiation & Formal Collaboration Optimisation Formalised (client testing & commercial integrati
Slide 16: Technology Development
Quality and Consistency Technology Development 16
Slide 17: Quality and Consistency
=> LifeChain’ 0) Quality and Consistency
Slide 18: Operational Highlights – Hardware (VCU2)
Operational Highlights – Hardware (VCU2) Vitrafy has designed a commercial-ready product with a competitive edge Awarded $4.8m Continued innovation, building on the competitive advantage and IP ‘moat’ Increased performance and expanded functionality Increased reliability through refrigeration system
Slide 19: Operational Highlights – Hardware (VCU2)
Operational Highlights – Hardware (VCU2) Vitrafy has a clear and defined path to commercialisation in FY26 Phase 1 Phase 2 Medical Completed Q4 FY25 In progress Device H2 FY26 Innovation 1st Batch Build Verification and Detailed Design Customer feedback Validation (USA) Commercialisation Commerciali
Slide 20: Operational Highlights – Software
Operational Highlights – Software The LifeChain upgrade is a critical component in Current Program of work commercialisation, Architecture, Market delivering an enterprise-grade Infrastructure Release software & Functional Development with VCU2 Complete In progress Enhancing VCU2 functionality • Bui
Slide 21: Financial Results FY25
2 Financial Results FY25 21
Slide 22: Income Statement
Income Statement Summary Commentary: FY24 FY25 ($000’s) • Sales up 75% YoY, driven by Huon growth and Sales revenue 37 65 aquaculture pilot completion. Interest and Other Income 34 784 • ~$1m IGP grant earned, $2.4m cash received; remainder recorded as unearned revenue on Grant Income – 972 the bala
Slide 23: Normalised Income Statement
Normalised Income Statement Summary Normalised 1H FY24 2H FY24 FY24 1H FY25 2H FY25 FY25 ($000’s) Income FY25 Income 1,205 889 2,094 738 2,067 2,804 2,804 Administrative expenses (1,201) (1,475) (2,676) (3,770) (3,906) (7,675) (5,600) Research and development expenses (2,232) (2,016) (4,248) (2,323)
Slide 24: Balance Sheet
Balance Sheet Commentary: Summary FY24 FY25 ($000’s) • $29.6m cash and liquid assets on hand, including $10.1m in term deposits. Sales revenue 37 65 • Cash runway forecast through to CY2027 Interest and Other Income 34 784 with elevated expenditure in FY26. • Receivables include GST refund, term dep
Slide 25: Cash Flow
Cash Flow Summary ($000’s) FY24 FY25 Receipts from customers and other income 41 97 Payments to suppliers and employees (8,879) (14,078) Net interest received 34 517 R&D tax incentive received 2,013 2,023 Government grant received – 2,640 Operating cash flow (6,792) (8,801) Investments in term depos
Slide 26: Outlook
3 Outlook 26
Slide 27: FY26 Outlook
FY26 Outlook Vitrafy has a clear focus Market development Technology development on revenue-generating commercialisation activities Capture global commercial Unregulated product opportunities in animal launch H1 FY26 reproduction Expand paid human Medical Device product health collaborations launch
Slide 28: Questions
Questions 28
Slide 29: Thank You
Thank You Contacts Mr. Brent Owens Chief Executive Officer (from 1 September 2025), Co-Founder Email: bowens@vitrafy.com Simon Martin Chief Financial Officer Email: smartin@vitrafy.com Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com Strictly Private and Confidential